BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 38448914)

  • 1. CD133 significance in glioblastoma development: in silico and in vitro study.
    Abdoli Shadbad M; Nejadi Orang F; Baradaran B
    Eur J Med Res; 2024 Mar; 29(1):154. PubMed ID: 38448914
    [TBL] [Abstract][Full Text] [Related]  

  • 2. hsa-miR-34a-5p enhances temozolomide anti-tumoral effects on glioblastoma: in-silico and in-vitro study.
    Abdoli Shadbad M; Baghbanzadeh A; Baradaran B
    EXCLI J; 2024; 23():384-400. PubMed ID: 38655096
    [TBL] [Abstract][Full Text] [Related]  

  • 3. LIM and SH3 protein 1 regulates cell growth and chemosensitivity of human glioblastoma via the PI3K/AKT pathway.
    Zhong C; Chen Y; Tao B; Peng L; Peng T; Yang X; Xia X; Chen L
    BMC Cancer; 2018 Jul; 18(1):722. PubMed ID: 29980193
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Xihuang Pill-destabilized CD133/EGFR/Akt/mTOR cascade reduces stemness enrichment of glioblastoma via the down-regulation of SOX2.
    Xu L; Duan H; Zou Y; Wang J; Liu H; Wang W; Zhu X; Chen J; Zhu C; Yin Z; Zhao X; Wang Q
    Phytomedicine; 2023 Jun; 114():154764. PubMed ID: 36963368
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Silencing lncRNA LINC01410 suppresses cell viability yet promotes apoptosis and sensitivity to temozolomide in glioblastoma cells by inactivating PTEN/AKT pathway via targeting miR-370-3p.
    Fu T; Yang Y; Mu Z; Sun R; Li X; Dong J
    Immunopharmacol Immunotoxicol; 2021 Dec; 43(6):680-692. PubMed ID: 34435542
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of miR-579 on the PI3K/AKT pathway in human glioblastoma PTEN mutant cell lines.
    Kalhori MR; Irani S; Soleimani M; Arefian E; Kouhkan F
    J Cell Biochem; 2019 Oct; 120(10):16760-16774. PubMed ID: 31243804
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination Therapy with AKT3 and PI3KCA siRNA Enhances the Antitumor Effect of Temozolomide and Carmustine in T98G Glioblastoma Multiforme Cells.
    Paul-Samojedny M; Pudełko A; Kowalczyk M; Fila-Daniłow A; Suchanek-Raif R; Borkowska P; Kowalski J
    BioDrugs; 2016 Apr; 30(2):129-44. PubMed ID: 26902608
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Guggulsterone from Commiphora mukul potentiates anti-glioblastoma efficacy of temozolomide in vitro and in vivo via down-regulating EGFR/PI3K/Akt signaling and NF-κB activation.
    Xu HB; Chen XZ; Yu ZL; Xue F
    J Ethnopharmacol; 2023 Jan; 301():115855. PubMed ID: 36280019
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A HIF-independent, CD133-mediated mechanism of cisplatin resistance in glioblastoma cells.
    Ahmed EM; Bandopadhyay G; Coyle B; Grabowska A
    Cell Oncol (Dordr); 2018 Jun; 41(3):319-328. PubMed ID: 29492900
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epithelial membrane protein 1 promotes glioblastoma progression through the PI3K/AKT/mTOR signaling pathway.
    Miao L; Jiang Z; Wang J; Yang N; Qi Q; Zhou W; Feng Z; Li W; Zhang Q; Huang B; Chen A; Zhang D; Zhao P; Li X
    Oncol Rep; 2019 Aug; 42(2):605-614. PubMed ID: 31233190
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CLEC19A overexpression inhibits tumor cell proliferation/migration and promotes apoptosis concomitant suppression of PI3K/AKT/NF-κB signaling pathway in glioblastoma multiforme.
    Mohajerani F; Tehrankhah ZM; Rahmani S; Afsordeh N; Shafiee S; Pourgholami MH; Soltani BM; Sadeghizadeh M
    BMC Cancer; 2024 Jan; 24(1):19. PubMed ID: 38167030
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting the ABC transporter ABCB5 sensitizes glioblastoma to temozolomide-induced apoptosis through a cell-cycle checkpoint regulation mechanism.
    Lee CAA; Banerjee P; Wilson BJ; Wu S; Guo Q; Berg G; Karpova S; Mishra A; Lian JW; Tran J; Emmerich M; Murphy GF; Frank MH; Frank NY
    J Biol Chem; 2020 May; 295(22):7774-7788. PubMed ID: 32317280
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Synergistic Effect of Combination Progesterone and Temozolomide on Human Glioblastoma Cells.
    Atif F; Patel NR; Yousuf S; Stein DG
    PLoS One; 2015; 10(6):e0131441. PubMed ID: 26110872
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Wild‑type IDH1 affects cell migration by modulating the PI3K/AKT/mTOR pathway in primary glioblastoma cells.
    Shen X; Wu S; Zhang J; Li M; Xu F; Wang A; Lei Y; Zhu G
    Mol Med Rep; 2020 Sep; 22(3):1949-1957. PubMed ID: 32705169
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of Galbanic Acid on Proliferation, Migration, and Apoptosis of Glioblastoma Cells Through the PI3K/Akt/MTOR Signaling Pathway.
    Shahcheraghi SH; Lotfi M; Soukhtanloo M; Ghayour Mobarhan M; Jaliani HZ; Sadeghnia HR; Ghorbani A
    Curr Mol Pharmacol; 2021; 14(1):79-87. PubMed ID: 32394847
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SMAGP knockdown inhibits the malignant phenotypes of glioblastoma cells by inactivating the PI3K/Akt pathway.
    Ni H; Ji D; Huang Z; Li J
    Arch Biochem Biophys; 2020 Nov; 695():108628. PubMed ID: 33049294
    [TBL] [Abstract][Full Text] [Related]  

  • 17.
    Kim HI; Hong SH; Ku JM; Kim MJ; Ju SW; Chang SW; Cheon C; Ko SG
    Nutrients; 2020 Jan; 12(1):. PubMed ID: 31936835
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nuciferine inhibits the progression of glioblastoma by suppressing the SOX2-AKT/STAT3-Slug signaling pathway.
    Li Z; Chen Y; An T; Liu P; Zhu J; Yang H; Zhang W; Dong T; Jiang J; Zhang Y; Jiang M; Yang X
    J Exp Clin Cancer Res; 2019 Mar; 38(1):139. PubMed ID: 30922391
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HIF1α/HIF2α-Sox2/Klf4 promotes the malignant progression of glioblastoma via the EGFR-PI3K/AKT signalling pathway with positive feedback under hypoxia.
    Wang P; Zhao L; Gong S; Xiong S; Wang J; Zou D; Pan J; Deng Y; Yan Q; Wu N; Liao B
    Cell Death Dis; 2021 Mar; 12(4):312. PubMed ID: 33762574
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of phosphatidylinositol 3-kinase by PX-866 suppresses temozolomide-induced autophagy and promotes apoptosis in glioblastoma cells.
    Harder BG; Peng S; Sereduk CP; Sodoma AM; Kitange GJ; Loftus JC; Sarkaria JN; Tran NL
    Mol Med; 2019 Nov; 25(1):49. PubMed ID: 31726966
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.